The Race to Rewrite Clinical Research in Real Time

OpenEvidence secures over US$200 million across two rounds as AI driven evidence platforms accelerate toward wider clinical use

1 Dec 2025

OpenEvidence has secured more than $200mn in two funding rounds this year, underscoring strong investor interest in tools that deliver verified medical research to clinicians at the point of care. The July Series B valued the company at $3.5bn, while an October Series C doubled that figure, signalling growing confidence in the role of automated evidence systems in clinical practice.

The company’s platform is designed to save time for doctors by presenting relevant findings within seconds, avoiding searches through medical guidelines or research databases. OpenEvidence says its tools are already used by a large share of US physicians, citing internal data. Investors view this as part of a wider change in healthcare, where immediate access to vetted information is becoming standard.

The sector’s expansion reflects deeper partnerships between AI developers, medical publishers and professional groups. These agreements provide regular flows of peer-reviewed studies and aim to ease concerns among clinicians wary of automated recommendations. Analysts say this approach indicates a move toward specialised systems focused on precision and transparency in medical settings.

However, growth has brought closer scrutiny. Clinicians warn that automated tools must not compress complex research into overly simplified answers, particularly when evidence remains uncertain. Regulators are monitoring how platforms handle sensitive data and how their suggestions influence clinical decisions. A doctor at a major hospital said “reliability matters most when studies are incomplete”, noting the continued importance of human judgement. Other developers in the field are facing similar questions as safety and transparency take greater priority.

Despite these pressures, sentiment in digital health remains positive. Strong capital inflows and rising adoption suggest AI-based evidence tools are likely to become routine in hospitals and clinics. Observers expect continued investment to support faster and more accurate methods of gathering and interpreting medical research, offering clinicians and patients quicker insights and more confident decisions.